Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00388726
Registration number
NCT00388726
Ethics application status
Date submitted
13/10/2006
Date registered
17/10/2006
Date last updated
7/01/2020
Titles & IDs
Public title
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
Query!
Scientific title
The "EMBRACE" Trial: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-arm, Multi-center Study of E7389 Versus "Treatment of Physician's Choice" in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane
Query!
Secondary ID [1]
0
0
2006-001949-34
Query!
Secondary ID [2]
0
0
E7389-G000-305
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - E7389
Treatment: Drugs - Physician's Choice
Experimental: 1 -
Active Comparator: 2 -
Treatment: Drugs: E7389
1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
Treatment: Drugs: Physician's Choice
Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival
Query!
Assessment method [1]
0
0
Defined as the time from the date of randomization until the date of death from any cause.
Query!
Timepoint [1]
0
0
From date of randomization until death from any cause
Query!
Secondary outcome [1]
0
0
Progression-Free Survival.
Query!
Assessment method [1]
0
0
Measured using Response Evaluation Criteria in Solid Tumors (RECIST) and defined as the time from the date of randomization until progressive disease or death from any cause in the absence of of progressive disease.
Query!
Timepoint [1]
0
0
Until disease progression or death.
Query!
Secondary outcome [2]
0
0
Best Overall Response
Query!
Assessment method [2]
0
0
Measured by RECIST criteria and defined as the best response from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diameter), stable disease (SD-neither shrinkage nor increase of lesions).
Query!
Timepoint [2]
0
0
Until Day 30 or every 3 months during Follow-up period for patients who complete study without PD.
Query!
Secondary outcome [3]
0
0
Duration of Response.
Query!
Assessment method [3]
0
0
As measured by RECIST criteria and defined as the time from the first documented CR or PR until disease progression or death from any cause.
Query!
Timepoint [3]
0
0
From first documented CR or PR until disease progression or death.
Query!
Secondary outcome [4]
0
0
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
From start of study drug administration up to 30 days after the last dose of study drug (approximately up to 42 months)
Query!
Eligibility
Key inclusion criteria
1. Female patients with histologically or cytologically confirmed carcinoma of the
breast.
Every effort should be made to make paraffin embedded tissue or slides from the
diagnostic biopsy or surgical specimen available for confirmation of diagnosis.
2. Patients with locally recurrent or metastatic disease who have received at least two
(and not more than five) prior chemotherapeutic regimens for breast cancer, at least
two of which were administered for treatment of locally recurrent and/or metastatic
disease.
Prior therapy must be documented by the following criteria prior to entry onto study:
- Regimens must have included an anthracycline (e.g., doxorubicin, epirubicin) and
a taxane (e.g., paclitaxel, docetaxel) in any combination or order. Treatment
with any of these agents is not required if they are contraindicated for a
certain patient.
- One or two of these regimens may have been administered as adjuvant and/or
neoadjuvant therapy, but at least 2 must have been given for relapsed or
metastatic disease.
- Patients must have proved refractory to the most recent chemotherapy, documented
by progression on or within six (6) months of therapy.
- Patients with Human Epidermal Growth Factor 2 (HER2/neu) positive tumors may
additionally have been treated with trastuzumab.
- Patients may have additionally been treated with anti-hormonal therapy.
3. Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or
lower, except for stable sensory neuropathy <= Grade 2 and alopecia.
4. Age >= 18 years.
5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
6. Life expectancy of >= 3 months.
7. Adequate renal function as evidenced by serum creatinine <= 2.0 mg/dL or calculated
creatinine clearance >= 40 mL/min per the Cockcroft and Gault formula.
8. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) >= 1.5 x
10^9/L, hemoglobin >= 10.0 g/dL (a hemoglobin <10.0 g/dL is acceptable if it is
corrected by growth factor or transfusion), and platelet count >= 100 x 10^9/L.
9. Adequate liver function as evidenced by bilirubin <= 1.5 times the upper limits of
normal (ULN) and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate
aminotransferase (AST) <= 3 x ULN (in the case of liver metastases <= 5 x ULN), unless
there are bone metastases, in which case liver specific alkaline phosphatase must be
separated from the total and used to assess the liver function instead of the total
alkaline phosphatase. In case alkaline phosphatase is >3 x ULN (in absence of liver
metastases) or > 5 x ULN (in presence of liver metastases) AND patient is known to
have bone metastases, the liver specific alkaline phosphatase must be separated from
the total and used to assess the liver function instead of the total alkaline
phosphatase.
10. Patients willing and able to comply with the study protocol for the duration of the
study.
11. Written informed consent prior to any study-specific screening procedures with the
understanding that the patient may withdraw consent at any time without prejudice.
EXCLUSION CRITERIA
1. Patients who have received any of the following treatments within the specified period
before E7389 or TPC treatment start:
- chemotherapy, radiation, trastuzumab or hormonal therapy within three weeks.
- any investigational drug within four weeks.
2. Radiation therapy encompassing > 30% of marrow.
3. Prior treatment with mitomycin C or nitrosourea.
4. Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring
active treatment, including the use of oxygen.
5. Patients with brain or subdural metastases are not eligible, unless they have
completed local therapy and have discontinued the use of corticosteroids for this
indication for at least 4 weeks before starting treatment in this study. Any signs
(e.g., radiologic) and/or symptoms of brain metastases must be stable for at least 4
weeks before starting study treatment; radiographic stability should be determined by
comparing a contrast-enhanced computed tomography or magnetic resonance imaging brain
scan performed during screening to a prior scan performed at least 4 weeks earlier.
6. Patients with meningeal carcinomatosis.
7. Patients who are receiving anti-coagulant therapy with warfarin or related compounds,
other than for line patency, and cannot be changed to heparin-based therapy if
randomized to E7389 are not eligible. If a patient is to continue on mini-dose
warfarin, then the prothrombin time (PT) or international normalized ratio (INR) must
be closely monitored.
8. Women who are pregnant or breast-feeding; women of childbearing potential with either
a positive pregnancy test at screening or no pregnancy test; women of childbearing
potential unless (1) surgically sterile or (2) using adequate measures of
contraception in the opinion of the Investigator. Perimenopausal women must be
amenorrheic for at least 12 months to be considered of non-childbearing potential.
9. Severe/uncontrolled intercurrent illness/infection.
10. Significant cardiovascular impairment (history of congestive heart failure > New York
Heart Association grade II, unstable angina or myocardial infarction within the past
six months, or serious cardiac arrhythmia).
11. Patients with organ allografts requiring immunosuppression.
12. Patients with known positive HIV status.
13. Patients who have had a prior malignancy, other than previous breast cancer, carcinoma
in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was
diagnosed and definitively treated >= 5 years previously with no subsequent evidence
of recurrence.
14. Patients with pre-existing neuropathy > Grade 2.
15. Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical
derivative.
16. Patients who participated in a prior E7389 clinical trial whether or not E7389 was
received.
17. Patients with other significant disease or disorders that, in the Investigator's
opinion, would exclude the patient from the study.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
762
Query!
Recruitment in Australia
Recruitment state(s)
QLD,SA
Query!
Recruitment hospital [1]
0
0
The Queen Elizabeth Hospital - Southport
Query!
Recruitment hospital [2]
0
0
Servicio De Oncologia - Woodville South
Query!
Recruitment hospital [3]
0
0
Maroondah Breast Clinic - Melbourne
Query!
Recruitment hospital [4]
0
0
Mater Medical Centre - North Sydney
Query!
Recruitment hospital [5]
0
0
Mount Hospital - Perth
Query!
Recruitment hospital [6]
0
0
Royal Perth Hospital, Department of Medical Oncology - Perth
Query!
Recruitment postcode(s) [1]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [2]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [3]
0
0
3135 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
2060 - North Sydney
Query!
Recruitment postcode(s) [5]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Iowa
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Montana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Nevada
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Oregon
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Buenos Aires
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Pcia. Santa Fe
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
San Miguel De Tucuman
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Cordoba
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Rosario Santa Fe
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Santa Fe
Query!
Country [25]
0
0
Austria
Query!
State/province [25]
0
0
Graz Steiermark
Query!
Country [26]
0
0
Austria
Query!
State/province [26]
0
0
Salzburg
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Brussels
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Bruxelles
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Charleroi
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Gent
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Kortrijk
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
CE
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
GO
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
PA
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
RJ
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
RS
Query!
Country [37]
0
0
Brazil
Query!
State/province [37]
0
0
SP
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Ontario
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Quebec
Query!
Country [40]
0
0
Croatia
Query!
State/province [40]
0
0
Osijek
Query!
Country [41]
0
0
Croatia
Query!
State/province [41]
0
0
Zagreb
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Brno
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Jihlava
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Prague
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Praha 10
Query!
Country [46]
0
0
Czechia
Query!
State/province [46]
0
0
Praha
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Agners Cedex 01
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Besancon
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Bordeaux
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Caen Cedex 05
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Clermont-Ferrand Cedex 01
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Dijon Cedex
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Lyon
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Paris
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Saint Brieuc Cedex
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Tours Cedex
Query!
Country [57]
0
0
Hungary
Query!
State/province [57]
0
0
Budapest
Query!
Country [58]
0
0
Hungary
Query!
State/province [58]
0
0
Debrecen
Query!
Country [59]
0
0
Hungary
Query!
State/province [59]
0
0
Pecs
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Szombathely
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Firenze (FI)
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Genova
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Lecce (LE)
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Milano
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Roma
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Rozzano
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Sora
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Gdansk
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Gdynia
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Gilwice
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Krakow
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Poznan
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Szczecin
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Warszawa
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Izhervsk Udmurtia
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Kazan
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
Krasnodar
Query!
Country [78]
0
0
Russian Federation
Query!
State/province [78]
0
0
Moscow
Query!
Country [79]
0
0
Russian Federation
Query!
State/province [79]
0
0
Nizhny Novgorod
Query!
Country [80]
0
0
Russian Federation
Query!
State/province [80]
0
0
Novosibirisk
Query!
Country [81]
0
0
Russian Federation
Query!
State/province [81]
0
0
Petrozavodsk
Query!
Country [82]
0
0
Russian Federation
Query!
State/province [82]
0
0
Pyatigorsk
Query!
Country [83]
0
0
Russian Federation
Query!
State/province [83]
0
0
St Petersburg
Query!
Country [84]
0
0
Russian Federation
Query!
State/province [84]
0
0
St. Petersburg
Query!
Country [85]
0
0
Russian Federation
Query!
State/province [85]
0
0
Tomsk
Query!
Country [86]
0
0
Russian Federation
Query!
State/province [86]
0
0
Yaroslavl
Query!
Country [87]
0
0
South Africa
Query!
State/province [87]
0
0
Cape Town
Query!
Country [88]
0
0
South Africa
Query!
State/province [88]
0
0
Eastern Cape
Query!
Country [89]
0
0
South Africa
Query!
State/province [89]
0
0
Johannesburg
Query!
Country [90]
0
0
South Africa
Query!
State/province [90]
0
0
Pretoria
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Barcelona
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Gerona
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Jaen
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Salamanca
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Santa Cruz de Tenerife
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Sevilla
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Zanagoza
Query!
Country [98]
0
0
Switzerland
Query!
State/province [98]
0
0
Aarau
Query!
Country [99]
0
0
Switzerland
Query!
State/province [99]
0
0
Bern Bern
Query!
Country [100]
0
0
Switzerland
Query!
State/province [100]
0
0
St. Gallen
Query!
Country [101]
0
0
Switzerland
Query!
State/province [101]
0
0
Thun
Query!
Country [102]
0
0
Switzerland
Query!
State/province [102]
0
0
Winterhur
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eisai Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Eisai Limited
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to compare Overall Survival (OS), Progression Free Survival
(PFS), objective tumor response rate, duration of response, and safety in patients treated
with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally
recurrent or metastatic breast cancer.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00388726
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00388726
Download to PDF